|
|
 Previous Article | Table of Contents | Next Article 
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with
plasma cell leukemia
B Klein, J Wijdenes, XG Zhang, M Jourdan, JM Boiron, J Brochier, J Liautard, M Merlin, C Clement and B Morel-Fournier
INSERM U291, Montpellier, France.
A patient with primary plasma cell leukemia resistant to chemotherapy was
treated for 2 months with daily intravenous injections of anti-
interleukin-6 (IL-6) monoclonal antibodies (MoAbs). The patient's clinical
status improved throughout the treatment and no major side effects were
observed. Serial monitoring showed blockage of the myeloma cell
proliferation in the bone marrow (from 4.5% to 0% myeloma cells in the
S-phase in vivo) as well as reduction in the serum calcium, serum
monoclonal IgG, and the serum C-reactive protein levels. The serum calcium
and serum monoclonal IgG corrected by approximately 30%, whereas the
C-reactive protein corrected to undetectable levels during treatment. No
major side effects developed, although both platelet and circulating
neutrophil counts decreased during anti-IL-6 therapy. A transient
immunization was detected 15 days after the initiation of the treatment,
which could explain the recovery of myeloma cell proliferation after 2
months of treatment (2% myeloma cells in the S phase). In conclusion, this
first anti-IL-6 clinical trial demonstrated the feasibility of injecting
anti-IL-6 MoAbs, and also a transient tumor cytostasis and a reduction in
IL-6-related toxicities. It gave insight into the major biologic activities
of IL-6 in vivo and may serve as a basis for further development of
anti-IL-6 therapy in myeloma and other IL-6-related diseases.
Volume 78,
Issue 5,
pp. 1198-1204,
09/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Duplomb, M. Baud'huin, C. Charrier, M. Berreur, V. Trichet, F. Blanchard, and D. Heymann
Interleukin-6 Inhibits Receptor Activator of Nuclear Factor {kappa}B Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727 Phosphorylation of Signal Transducer and Activator of Transcription 3
Endocrinology,
July 1, 2008;
149(7):
3688 - 3697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Kasaian, X.-Y. Tan, M. Jin, L. Fitz, K. Marquette, N. Wood, T. A. Cook, J. Lee, A. Widom, R. Agostinelli, et al.
Interleukin-13 Neutralization by Two Distinct Receptor Blocking Mechanisms Reduces Immunoglobulin E Responses and Lung Inflammation in Cynomolgus Monkeys
J. Pharmacol. Exp. Ther.,
June 1, 2008;
325(3):
882 - 892.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Richey, J. R. George, M. E. Couch, B. K. Kanapkey, X. Yin, T. Cannon, P. W. Stewart, M. C. Weissler, and C. G. Shores
Defining Cancer Cachexia in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res.,
November 15, 2007;
13(22):
6561 - 6567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, D. Hose, T. Reme, E. Jourdan, M. Hundemer, E. Legouffe, P. Moine, P. Bourin, M. Moos, J. Corre, et al.
CD200 is a new prognostic factor in multiple myeloma
Blood,
December 15, 2006;
108(13):
4194 - 4197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Unsal, S Aksaray, D Koksal, and T Sipit
Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis
Postgrad. Med. J.,
September 1, 2005;
81(959):
604 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Liu, H. Ishikawa, F.-J. Li, Z. Ma, K.-i. Otsuyama, H. Asaoku, S. Abroun, X. Zheng, N. Tsuyama, M. Obata, et al.
Dehydroepiandrosterone Can Inhibit the Proliferation of Myeloma Cells and the Interleukin-6 Production of Bone Marrow Mononuclear Cells from Patients with Myeloma
Cancer Res.,
March 15, 2005;
65(6):
2269 - 2276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J.-F. Rossi, B. Klein, and K. Tarte
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
Blood,
April 15, 2004;
103(8):
3148 - 3157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi
Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence
Clin. Cancer Res.,
October 15, 2003;
9(13):
4653 - 4665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler
Signal transducer and activator of transcription proteins in leukemias
Blood,
April 15, 2003;
101(8):
2940 - 2954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, M. Talpaz, and Z. Estrov
Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies
Clin. Cancer Res.,
February 1, 2003;
9(2):
535 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Varghese, R. L. Moritz, M.-Z. Lou, A. van Donkelaar, H. Ji, N. Ivancic, K. M. Branson, N. E. Hall, and R. J. Simpson
Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain
PNAS,
December 10, 2002;
99(25):
15959 - 15964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner
IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-{kappa}B Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvariae
J. Immunol.,
September 15, 2002;
169(6):
3353 - 3362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J.-F. Rossi, J. Shaughnessy Jr, et al.
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Blood,
July 30, 2002;
100(4):
1113 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Haddad, S. Paczesny, V. Leblond, J.-M. Seigneurin, M. Stern, A. Achkar, M. Bauwens, V. Delwail, D. Debray, C. Duvoux, et al.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
Blood,
March 15, 2001;
97(6):
1590 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nishimoto, T. Kishimoto, and K. Yoshizaki
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Ann Rheum Dis,
November 1, 2000;
59(90001):
i21 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ogawa, T. Nishiura, K. Oritani, H. Yoshida, M. Yoshimura, Y. Okajima, J. Ishikawa, K. Hashimoto, I. Matsumura, Y. Tomiyama, et al.
Cytokines Prevent Dexamethasone-induced Apoptosis via the Activation of Mitogen-activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways in a New Multiple Myeloma Cell Line
Cancer Res.,
August 1, 2000;
60(15):
4262 - 4269.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. C. Manolagas
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis
Endocr. Rev.,
April 1, 2000;
21(2):
115 - 137.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Nishimoto, M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, T. Kishimoto, and K. Yoshizaki
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
Blood,
January 1, 2000;
95(1):
56 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Bernstein
Mechanisms of Therapeutic Activity for Gallium
Pharmacol. Rev.,
December 1, 1998;
50(4):
665 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Renne, K.-J. Kallen, J. Mullberg, T. Jostock, J. Grotzinger, and S. Rose-John
A New Type of Cytokine Receptor Antagonist Directly Targeting gp130
J. Biol. Chem.,
October 16, 1998;
273(42):
27213 - 27219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4727 - 4737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Krebs, H. Griffin, G. Winter, and S. Rose-John
Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6. SPECIFIC TARGETING OF CYTOKINE-SECRETING CELLS
J. Biol. Chem.,
January 30, 1998;
273(5):
2858 - 2865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Said, M. R. Rettig, K. Heppner, R. A. Vescio, G. Schiller, H. J. Ma, D. Belson, A. Savage, I. P. Shintaku, H. P. Koeffler, et al.
Localization of Kaposi's Sarcoma-Associated Herpesvirus in Bone Marrow Biopsy Samples From Patients With Multiple Myeloma
Blood,
December 1, 1997;
90(11):
4278 - 4282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ozaki, M. Kosaka, S. Wakatsuki, M. Abe, Y. Koishihara, and T. Matsumoto
Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24
Blood,
October 15, 1997;
90(8):
3179 - 3186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bataille and J.-L. Harousseau
Multiple Myeloma
N. Engl. J. Med.,
June 5, 1997;
336(23):
1657 - 1664.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Salvati, A. Lahm, G. Paonessa, G. Ciliberto, and C. Toniatti
Interleukin-6 (IL-6) Antagonism by Soluble IL-6 Receptor [IMAGE] Mutated in the Predicted gp130-binding Interface
J. Biol. Chem.,
May 19, 1995;
270(20):
12242 - 12249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ehlers, F. D. de Hon, H. K. Bos, U. Horsten, Gün. Kurapkat, H. S. van De Leur, J. Grötzinger, A. Wollmer, J. P. J. Brakenhoff, and S. Rose-John
Combining Two Mutations of Human Interleukin-6 That Affect gp130 Activation Results in a Potent Interleukin-6 Receptor Antagonist on Human Myeloma Cells
J. Biol. Chem.,
April 7, 1995;
270(14):
8158 - 8163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Manolagas and R. L. Jilka
Bone Marrow, Cytokines, and Bone Remodeling -- Emerging Insights into the Pathophysiology of Osteoporosis
N. Engl. J. Med.,
February 2, 1995;
332(5):
305 - 311.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Beck, S.-M. Hsu, J. Wijdenes, R. Bataille, B. Klein, D. Vesole, K. Hayden, S. Jagannath, and B. Barlogie
Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody
N. Engl. J. Med.,
March 3, 1994;
330(9):
602 - 605.
[Full Text]
|
|
|
|
|
|
|
T Kishimoto, S Akira, and T Taga
Interleukin-6 and its receptor: a paradigm for cytokines
Science,
October 23, 1992;
258(5082):
593 - 597.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Jilka, G Hangoc, G Girasole, G Passeri, D. Williams, J. Abrams, B Boyce, H Broxmeyer, and S. Manolagas
Increased osteoclast development after estrogen loss: mediation by interleukin-6
Science,
July 3, 1992;
257(5066):
88 - 91.
[Abstract]
[PDF]
|
|
|
|
|
